Biotest (EM)【BIESF】銘柄情報

Biotest AG (EM) (BIESF) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

32.00

( - )

買値

0.00

売値

0.00

出来高

平均取引量 (3 か月)

US$ 895

財務取引量

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

1.266B

企業価値

2.048B

前日終値

32.00

始値

時刻

最終取引時間

VWAP

歳入

648.9M

純利益

-70.7M

発行済株式数

39,571,452

浮動株比率 (%)

100.00%

機関投資家保有比率 (%)

0.201969%

配当利回り

0.04 (0.1851%)

PER

-18.47

株価売上高倍率 (PSR)

2.01

1 株当たり利益 (EPS)

-1.79

ベータ

Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemocti... Biotest GmbH & Co. KGaA develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomegalovirus infection in patients undergoing immunosuppressive therapy; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect CP for prophylaxis and immunoprophylaxis of hepatitis B; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes, as well as autoimmune diseases, including neurological indications, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barré syndrome, immune thrombocytopenia, and Kawasaki syndrome; Varitect for prophylaxis and treatment of varicella zoster virus infections; and Zutectra for prophylaxis and treatment of hepatitis B reinfection following liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for community-acquired pneumonia; and Pentaglobin to treat bacterial infections. The company has a technology transfer and licensing agreement with Grifols, S.A. for the manufacture and marketing of Yimmugo, Fibrinogen, and Trimodulin. Biotest GmbH & Co. KGaA was founded in 1946 and is headquartered in Dreieich, Germany. Biotest GmbH & Co. KGaA operates as a subsidiary of Grifols Biotest Holdings GmbH. 詳細を表示

セクター

業界

ウェブサイト

www.biotest.com

本社

Dreieich, Germany

設立

2026

Biotest AG (EM) is listed in the sector of the その他OTC with ticker BIESF. The last closing price for Biotest (EM) was US$32. Over the last year, Biotest (EM) shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Biotest (EM) currently has 39,571,452 shares in issue. The market capitalisation of Biotest (EM) is US$1.27 billion. Biotest (EM) has a price to earnings ratio (PE ratio) of -18.47.

表示するニュースはありません。